Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027
Reviewed 20 sourcesPublished by PepVault
On Jan 1, 2027 Wegovy and Ozempic list at $675 a month, Medicare's $274 semaglutide price starts, the $50 GLP-1 Bridge runs on, and GLP-1s stay legal in sport.

- Last reviewed
- Sources
- 20
- Questions
- 8
- Compounds
- 3
The short answer
On January 1, 2027, Novo Nordisk's announced $675 monthly list price for Wegovy, Ozempic and Rybelsus takes effect, which can lower costs for people on a deductible or coinsurance, not for self-pay buyers. Medicare's negotiated $274 monthly price for semaglutide starts. The $50 Medicare GLP-1 Bridge runs through 2027. WADA's 2027 list keeps GLP-1s permitted and names unapproved peptides as banned.
Evidence: Prices and rules from the makers', CMS's and WADA's own pages, read November 20, 2026; Novo's January 1 list price is the company's announced plan, while the Medicare prices, the Part D limits and the WADA list are fixed.

What changes for GLP-1 users on January 1, 2027?
Seven things change on that day or are settled by it; the table shows each one and whether it is fixed or a plan. Fixed: Medicare's negotiated price for semaglutide8, the 2027 Part D deductible and cap9, and WADA's 2027 Prohibited List1415. Novo Nordisk's lower list price is the company's announced plan1. Medicare's BALANCE model, due in Part D on January 1, will not start1213.
| What | Who it affects | Before | From January 1, 2027 | Status and source |
|---|---|---|---|---|
| Novo Nordisk list price (wholesale acquisition cost) | People whose share follows the list price: deductibles, coinsurance | Wegovy $1,349.02, Ozempic $1,027.51 per package | $675 a month for Wegovy 2.4 mg and 25 mg tablets, Ozempic 0.5, 1 and 2 mg, Rybelsus 7 and 14 mg | Company's announced plan; Novo Nordisk123 |
| NovoCare self-pay prices | People paying cash through NovoCare | Wegovy and Ozempic pens $199 for a new patient's first two months, then $349 for most strengths | The $199 offer ends December 31, 2026; Novo says pricing will be updated after that date | Offer end date set; new prices not yet published; NovoCare419 |
| Medicare negotiated price for semaglutide | Medicare Part D plans, and members whose share is a percentage | No negotiated price (2024 list price $959 a month) | $274 for a 30-day supply of Ozempic, Rybelsus or Wegovy; $385.63 for a box of four Wegovy 2.4 mg pens | Fixed by law and agreement; CMS8 |
| Part D deductible and yearly cap | Every Medicare Part D member | Deductible $615, out-of-pocket cap $2,100 | Deductible $700, out-of-pocket cap $2,400 | Fixed; CMS9 |
| Medicare GLP-1 Bridge | Eligible Part D members using a GLP-1 for weight | $50 copay, July 1 to December 31, 2026 | Unchanged: $50 copay, now through December 31, 2027 | Set by CMS; CMS, Medicare.gov1011 |
| BALANCE model in Part D | Part D plans and members | Scheduled to start January 1, 2027 | Not launching; no new date | CMS decision; CMS, KFF1213 |
| WADA Prohibited List | Athletes in WADA-code sport | 2026 list | 2027 list in force; GLP-1s still permitted and monitored; "peptides" added to S0's examples | Fixed, published list; WADA14151617 |
Whatever January changes about how you pay, your record stays yours: PepVault logs each dose and weigh-in, and Profile, Your data exports it all as a CSV to bring to a new plan or prescriber. Log it in PepVault

Does the Wegovy and Ozempic price cut lower what I pay?
It depends on which price you pay, and most people do not pay the list price. The list price, or wholesale acquisition cost, is what Novo charges wholesalers before any rebate. On February 24, 2026, Novo announced that from January 1, 2027 it falls to $675 a month across the strengths it named, about 50% below Wegovy's current list price and about 35% below Ozempic's1. NovoCare lists all three Wegovy forms (pen, HD pen and pill) at $1,349.02 a package today, and Ozempic at $1,027.5123.
| How you pay | Does January 1 change your price? | Why |
|---|---|---|
| High-deductible plan, before the deductible is met | Likely lower (Novo's stated aim) | Novo says the cut is meant for people whose costs are tied to the list price and names high-deductible plans1; your plan's price for the drug decides |
| Coinsurance (a percentage of the price) | Likely lower (Novo's stated aim) | Novo names coinsurance designs too1; if your plan's price follows the list price, your percentage is taken of a smaller number |
| Flat copay on a commercial plan | Probably not (our reading) | Your plan sets a flat copay, and no source ties it to the list price; the $25 savings card is a separate Novo program4 |
| Self-pay through NovoCare | Not by this cut | Novo says the list price change does not affect direct-to-patient self-pay prices1; the $199 starter offer ends December 31, 20264 |
| Medicare Part D, type 2 diabetes | Medicare's price falls | The negotiated $274 price starts the same day8; whether your own share falls depends on your plan's design |
| Medicare GLP-1 Bridge | No | The copay is a flat $501011 |
Novo's release lists Wegovy 2.4 mg and the 25 mg tablets, Ozempic 0.5, 1 and 2 mg, and Rybelsus 7 and 14 mg, and says the decision covers all doses of these medicines1. Wegovy HD 7.2 mg and the Ozempic pill, which NovoCare now lists, are not named in that February release; ask the pharmacy for the January price on those.
Is Zepbound or Mounjaro getting cheaper on January 1?
Lilly has not announced a January 1 list price change. On November 20, 2026, Lilly's own pricing pages gave Zepbound's list price as $499 to $1,086.37 a fill and Mounjaro's as $1,112.16, both from January 1, 2026 data, with no 2027 change stated56. None of Lilly's ten most recent press releases, to November 14, announces one7. Tirzepatide is also not among the 15 drugs whose Medicare negotiated prices start in 20278.
What changes for Medicare GLP-1 users on January 1?
Three things, and one thing that stays the same. First, Medicare's negotiated price for semaglutide takes effect: $274 for a 30-day supply of Ozempic, Rybelsus or Wegovy, 71% below the 2024 list price of $959, and $385.63 for a box of four Wegovy 2.4 mg pens8. That is what Medicare pays, not your copay, and Part D plans must carry the drug on their formularies8. CMS estimates that people with Part D save about $685 million out of pocket in 2027 under the standard benefit, across all 15 negotiated drugs8.
Second, the Part D standard benefit resets for the new year: the deductible rises from $615 to $700 and the yearly out-of-pocket cap from $2,100 to $2,4009. Third, BALANCE, the CMS model that was to cover GLP-1s for weight in Part D from January 1, 2027, will not launch as scheduled13. CMS's BALANCE page names no new Part D date; in Medicaid, states can join the model through January 1, 202712.
What stays the same is the Medicare GLP-1 Bridge. CMS extended it to run from July 1, 2026 to December 31, 202710. It covers Foundayo, Wegovy (pen or pill) and the Zepbound KwikPen for a $50 copay a month, and the $50 counts toward neither the Part D deductible nor the yearly cap1011. The Bridge runs on its own price: the makers supply its drugs at a net $245 a month20. A prior authorization, Medicare's approval request, is valid through December 31, 2027, refills and dose changes included, unless you change to a different GLP-111.
Who qualifies for the Medicare GLP-1 Bridge in 2027?
The rules do not change at the new year. You must be 18 or older and meet one of three paths when you start the drug, measured by body mass index (BMI, weight against height)11:
- BMI 35 or higher.
- BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher.
- BMI 27 or higher with prediabetes, a past heart attack or stroke, or peripheral artery disease with symptoms.
People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease are not in the Bridge, and neither is anyone whose Part D plan already covers their GLP-1; their Part D plan may cover it instead11. Extra Help, Medicare's low-income subsidy, cannot lower the $5011. The cost guide walks through each way of paying, Bridge steps included.
Are GLP-1s banned in sport from January 1, 2027?
No. WADA's 2027 Prohibited List, approved by its Executive Committee on September 10, 2026, published on September 21 and in force from January 1, 2027, does not name semaglutide or tirzepatide1415. WADA says their status is unchanged for 2027 "pending further data" on effects in athletes: its expert group found not enough evidence that they meet the criteria for the list, one sport study is running and WADA has started a second14.
They stay on WADA's Monitoring Program, the list of permitted substances it tracks for patterns of misuse: the 2027 program names semaglutide and tirzepatide, in and out of competition17. In 2026 it monitored "markers" of the two18.
For research peptides, the 2027 list makes the rule plainer. S0, the class for substances with no government approval for human use, now names "peptides" among its examples, beside drugs in development and veterinary-only drugs, and still names BPC-15715. WADA's note on the change: even a peptide the list does not name may still be prohibited16. The 2027 list also adds SLU-PP-332 and SLU-PP-915 to the metabolic modulators in S416. The full compound-by-compound list, and the NCAA's, is in the drug-test guide.
What should I do before January 1?
- Find your line in the table above: check your plan's drug benefit for whether Wegovy or Ozempic has a flat copay, coinsurance, or sits under your deductible.
- If you pay coinsurance or are under a deductible, ask the pharmacy in early January what your fill costs at the new list price1.
- If you started on NovoCare's $199 Wegovy or Ozempic offer, check NovoCare's prices after December 31, 2026, when the offer ends419.
- If you are on the Medicare GLP-1 Bridge, keep the same drug: your approval holds through December 31, 2027, and changing GLP-1s needs a new one11.
- If you are on Part D for type 2 diabetes, plan for the new $700 deductible and $2,400 cap in your January budget9.
- If you compete under a WADA code, look up anything beyond your prescribed GLP-1 on the 2027 list before January 115.
PepVault reminds you when each dose is due, so a January switch of pharmacy or program doesn't break the weekly rhythm. Set reminders in PepVault
What is still not decided?
Four things are open as of November 20, 2026. What Medicare does for GLP-1s for weight after the Bridge ends on December 31, 2027: KFF calls a lasting answer elusive, and CMS names no Part D date for BALANCE1213. NovoCare's self-pay prices from January, which Novo says it will update4. Whether Lilly changes Zepbound's or Mounjaro's list price56. And whether WADA's two studies change the status of GLP-1s for a later list; WADA says they should give it the data for a firm decision14. This page is dated and will be updated as each one is settled.
Sources
- Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (press release, Feb 24, 2026). novonordisk.com
- Novo Nordisk. NovoCare: Wegovy list price explained (read Nov 20, 2026). novocare.com
- Novo Nordisk. NovoCare: Ozempic list price explained (read Nov 20, 2026). novocare.com
- Novo Nordisk. NovoCare: Wegovy savings offer and self-pay prices (offer through Dec 31, 2026; read Nov 20, 2026). novocare.com
- Eli Lilly. Lilly Pricing Info: Zepbound list price (WAC accessed Jan 1, 2026; read Nov 20, 2026). pricinginfo.lilly.com
- Eli Lilly. Lilly Pricing Info: Mounjaro list price (WAC accessed Jan 1, 2026; read Nov 20, 2026). pricinginfo.lilly.com
- Eli Lilly. Press releases, the ten most recent to Nov 14, 2026 (read Nov 20, 2026). lilly.com
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2027 (fact sheet). cms.gov
- Centers for Medicare & Medicaid Services. Announcement of CY 2027 Medicare Advantage capitation rates and Part C and Part D payment policies (Apr 6, 2026): Part D benefit parameters. cms.gov
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge (page last modified Jul 13, 2026; read Nov 20, 2026). cms.gov
- Medicare.gov. Weight loss drugs: the Medicare GLP-1 Bridge (read Nov 20, 2026). medicare.gov
- Centers for Medicare & Medicaid Services. BALANCE Model (page last modified Sep 29, 2026; read Nov 20, 2026). cms.gov
- Cubanski J. CMS extends Medicare's short-term Bridge program for GLP-1 obesity drug coverage. KFF, Apr 23, 2026. kff.org
- World Anti-Doping Agency. WADA publishes 2027 Prohibited List (news release, Sep 21, 2026). wada-ama.org
- World Anti-Doping Agency. The 2027 Prohibited List (International Standard), in force 1 January 2027. wada-ama.org
- World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes. wada-ama.org
- World Anti-Doping Agency. The 2027 Monitoring Program. wada-ama.org
- World Anti-Doping Agency. The 2026 Monitoring Program. wada-ama.org
- Novo Nordisk. NovoCare: Ozempic savings offer and self-pay prices (offer through Dec 31, 2026; read Nov 20, 2026). novocare.com
- KFF. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. Updated May 11, 2026. kff.org
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.